Gami­da Cell to go pri­vate; Stoke aims to raise $75M

Plus, news about a TUD­CA study, PDS Biotech­nol­o­gy and Al­lar­i­ty Ther­a­peu­tics:

Gami­da Cell to go pri­vate: The com­mer­cial-stage cell ther­a­py biotech will no longer trade on the Nas­daq af­ter High­bridge Cap­i­tal Man­age­ment, its prin­ci­pal lender, re­struc­tures the com­pa­ny. The pen­ny stock $GM­DA was down 84% in Wednes­day trad­ing. Gami­da se­cured FDA ap­proval for its cell ther­a­py Omisirge in April. Then, in Jan­u­ary, it said it was “ac­tive­ly pur­su­ing” al­ter­na­tive routes to keep go­ing. — Kyle LaHu­cik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER